Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Baird Small/Mid Cap Growth Equity Fund 2024 Q4 Investor Letter | Buyside Digest

Back to Fund Profile (Baird Small/Mid Cap Growth Equity Fund)

Primary Source Intelligence • Q4 2024 Letter Analysis

Baird Small/Mid Cap Growth Equity Fund Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Baird Small/Mid Cap Growth Equity Fund. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

Annualized+9.13%

Digest Analysis

Quick Take

"Baird Small/Mid Cap Growth outperformed in Q4 with strong healthcare and technology stock selection, led by Tarsus Pharmaceuticals product launch success and Astera Labs AI infrastructure surge."

Executive Summary

Baird Small/Mid Cap Growth Equity delivered strong Q4 outperformance with a 5.1% net return versus 2.4% for the Russell 2500 Growth Index, driven primarily by strong stock selection. Healthcare was the standout sector, with positive fundamentals across holdings including Tarsus Pharmaceuticals continuing its product launch, Neurocrine Biosciences receiving pipeline approval, and a new position in Masimo as a pure-play healthcare company. Technology contributed through Astera Labs, which surged over 150% on AI and data center infrastructure growth, leading to position trimming. The fund initiated Pure Storage to benefit from hyperscaler AI spending. Despite trailing for the full year, the manager remains confident in their investment process and notes the portfolio is more balanced than concentrated benchmarks. Key challenges include benchmark concentration in AI-related stocks and interest rate sensitivity in housing-exposed names. The team maintains conviction in their long-standing philosophy while actively managing positions based on fundamental outlooks and risk management.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

The fund demonstrates moderate-high conviction through specific position sizing decisions, named holdings with clear rationales, and active portfolio management. They trimmed Astera Labs after 150% gains, initiated specific positions like Pure Storage and Masimo with detailed investment theses, and made decisive sells. However, the diversified SMID cap approach and acknowledgment of uncertainty prevents a higher score.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The manager expresses cautious optimism with mixed signals. While disappointed with full-year performance, they note stronger performance in the final five months and remain confident in their investment process. However, they acknowledge ongoing challenges from benchmark concentration and uncertainty about timing of more favorable conditions.

Risk Appetite

15%

DefensiveAggressive

Defensive (15%)

The fund shows selective risk appetite with active position management. They trimmed strong performers like Astera Labs, sold positions facing challenges, and initiated new positions like Pure Storage and Masimo. The approach suggests measured risk-taking rather than aggressive deployment.

Capital Deployment

5%

De-riskingDeploying

De-risking (5%)

Capital deployment appears largely neutral with rotation activity. The fund sold several positions (MedPace, RxSight, Lamb Weston, ChampionX, Axcelis, AppFolio, CACI) while initiating new ones (Masimo, Pure Storage) and trimming others. This represents portfolio rotation rather than net deployment or de-risking, with no specific cash level changes mentioned.

Forward Guidance

10%

CautiousExpansionary

Cautious (10%)

Forward guidance is cautiously constructive but acknowledges uncertainty. The manager states the timing of a more favorable backdrop is uncertain while expressing confidence in their process. They identify potential catalysts for 2025 but maintain a measured approach to deployment.

Language Signal

20%

BearishBullish

Bearish (20%)

Language is balanced with both positive and cautious elements. Positive terms include strong outperformance, encouraging catalysts, and confidence in process. Cautious language includes disappointment with full-year results, ongoing challenges, and uncertainty about timing.

Perceived Risk

45%

Low RiskElevated

Moderate Risk (45%)

The manager acknowledges moderate risks including benchmark concentration challenges, interest rate sensitivity for housing-exposed names, and potential biotech funding headwinds. However, these are discussed as manageable challenges rather than systemic threats, and the manager maintains confidence in their approach.

Opportunity Density

60%

ScarceAbundant

Selective (60%)

The manager demonstrates selective opportunity identification with specific new positions initiated and clear rationales for holdings. They identify encouraging catalysts for 2025 and maintain conviction in their stock selection ability, though they acknowledge the challenging environment for their investment style.

Time Horizon

70%

Short-TermLong-Term

Decade+ (70%)

The fund demonstrates a multi-year investment horizon with references to long-standing investment process, nine-year track record, and expectations for catalysts in 2025. They emphasize remaining steadfast to their philosophy and building a strong investment record over time, indicating patience beyond quarterly results.